One particular illustration is the development of the BCR-ABL allosteric inhibitor GNF-2 that can conquer the outcome of resistant mutations in addition to reveals a heightened potency when used together with typical ATP-competitive inhibitors24, but there is evidence that in virtually all the instances it can be either a secondary mutation or simp